GoPro Inc GPRO

GoPro, Inc. provides cameras, mountable and wearable accessories, and subscription and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides HERO13 Black, HERO12 Black, HERO11 Black, HERO10 Black, HERO, and MAX cameras; Premium and Premium+ subscription, which are subscription services that include cloud storage for its content; and Quik subscription, a subscription service in total addressable market to those who value organizing the visual moments of their lives with footage from any phone or camera. It also offers mobile and web applications, and desktop plugins that provide a media workflow for archiving, editing, multi-clip story creation, and sharing content on the fly; and a lifestyle gear lineup that melds its signature design and versatility across a line of bags, backpacks, and cases, as well as a line of t-shirts, hats, and other soft goods. In addition, the company provides mounts and accessories; equipment-based mounts com...

NDAQ:GPRO - Post by User

GoPro Inc

<< Previous

Bullboard Posts

Next >>

(0)
•••

Post by NatashaRomanon Apr 08, 2022 10:32pm

173 Views

Post# 34589925

FSD: Cancellation of Certain Shares Issued to Former CEO

FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today, pursuant to a court endorsement, the cancellation of 504,888 Class B subordinate voting shares previously issued to the Company’s former Chief Executive Officer, Dr. Raza Bokhari. This follows the prior cancellation of 156,278 Class B subordinate voting shares previously issued to certain former directors of the Company.

To cancel the shares previously issued to Dr. Raza Bokhari, FSD was forced to seek an order from the Ontario Superior Court. An application seeking a Court order was filed by FSD on July 21, 2021, with a hearing taking place on December 20, 2021. On March 8, 2022, the Court issued a decision that enabled the Company to cancel the 504,888 shares. The cancellation was completed on March 31, 2022. The Company’s President and Executive Co-Chairman of the Board, Zeeshan Saeed, stated that “The Company is pleased by this victory for its shareholders. This is an important step in addressing inappropriate conduct by the Company’s former board of directors and former Chief Executive Officer Dr. Raza Bokhari.”

About FSD Pharma
FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (“FSD BioSciences”), a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (“Lucid”), a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.

Contacts

Zeeshan Saeed, Founder, President and Executive Co-Chairman of the Board, FSD Pharma Inc.
Email: Zsaeed@fsdpharma.com
Telephone: (416) 854-8884
Investor Relations: Email: ir@fsdpharma.com , info@fsdpharma.com
Website: www.fsdpharma.com

<< Previous

Bullboard Posts

Next >>

How to pick AI stocks built to thrive through a potential bubble